Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2015 Publisher: Glaxo Wellcome UK Ltd, T/A GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Zantac Injection 50 mg/2ml.
| Pharmaceutical Form |
|---|
|
Injection (Aqueous solution). A clear colourless to pale yellow liquid, practically free from particles. |
Ranitidine Hydrochloride HSE 56.0 mg/2ml equivalent to Ranitidine 50.0 mg/2ml.
Each ampoule contains 2.9 mg (0.09 mmol) of sodium and 0.6 mg (0.015 mmol) of potassium.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Ranitidine |
Ranitidine is a specific rapidly acting histamine H2-antagonist. It inhibits basal and stimulated secretion of gastric acid, reducing both the volume and the acid and pepsin content of the secretion. Ranitidine has a relatively long duration of action and so a single 150 mg dose effectively suppresses gastric acid secretion for twelve hours. |
| List of Excipients |
|---|
|
Sodium chloride BP |
2 ml colourless Type I glass ampoules.
Pack size: 5 ampoules.
Glaxo Wellcome UK Ltd, T/A GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT
PL 10949/0109
25 March 1998
| Drug | Countries | |
|---|---|---|
| ZANTAC | Australia, Canada, Cyprus, Estonia, Hong Kong, Lithuania, New Zealand, Poland, Singapore, Turkey, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
